Page last updated: 2024-09-03

rb 6145 and EHS Tumor

rb 6145 has been researched along with EHS Tumor in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's8 (88.89)18.2507
2000's1 (11.11)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, GE; Cole, S; Fielden, EM; Naylor, MA; O'Neill, P; Stephens, MA; Stratford, IJ; Threadgill, MD; Webb, P1
Fitzmaurice, RJ; Lunt, SJ; Stratford, IJ; Telfer, BA; Williams, KJ1
Siemann, DW1
Adams, GE; Butler, SA; Cole, SM; Sansom, JM; Stratford, IJ; Szabo, C; Thiemermann, C; Wood, PJ1
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ1
Arnold, S; Chaplin, DJ; Collingridge, D; Hill, SA; Horsman, MR; Overgaard, J; Radacic, M; Wood, PJ1
Adams, GE; Cole, S; Elliott, W; Fielden, EM; Leopold, W; Sebolt-Leopold, J; Stratford, IJ; Suto, M1
Binger, M; Workman, P1
Adams, GE; Bowler, J; Cole, S; Lorimore, SA; Nolan, J; Stratford, IJ; Wright, EG1

Other Studies

9 other study(ies) available for rb 6145 and EHS Tumor

ArticleYear
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
    Journal of medicinal chemistry, 1991, Volume: 34, Issue:7

    Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Mice; Nitro Compounds; Radiation-Sensitizing Agents; Sarcoma, Experimental; Structure-Activity Relationship; Thiophenes

1991
Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-01, Volume: 11, Issue:11

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Female; Hypoxia; Mice; Mice, Inbred C3H; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tirapazamine; Treatment Outcome; Triazines

2005
Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1995, Volume: 34, Issue:1

    Topics: Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Lomustine; Mice; Nitroimidazoles; Prodrugs; Sarcoma, Experimental; Stereoisomerism; Tumor Cells, Cultured

1995
Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine.
    Cancer research, 1994, Dec-15, Volume: 54, Issue:24

    Topics: Animals; Arginine; Carcinoma; Cell Hypoxia; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Energy Metabolism; Female; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred C3H; Nitroarginine; Nitroimidazoles; Phosphates; Prodrugs; Sarcoma, Experimental

1994
Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
    International journal of radiation oncology, biology, physics, 1994, May-15, Volume: 29, Issue:2

    Topics: Animals; Antineoplastic Agents; Mice; Mice, Inbred C3H; Misonidazole; Mitomycin; Nitroimidazoles; Photochemotherapy; Sarcoma, Experimental

1994
Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours.
    The British journal of cancer. Supplement, 1996, Volume: 27

    Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Female; Hyperthermia, Induced; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred CBA; Nitroarginine; Nitroimidazoles; Regional Blood Flow; Sarcoma, Experimental

1996
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    International journal of radiation oncology, biology, physics, 1992, Volume: 22, Issue:3

    Topics: Animals; Cell Hypoxia; Combined Modality Therapy; Drug Evaluation; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental

1992
Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Cancer chemotherapy and pharmacology, 1991, Volume: 29, Issue:1

    Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Half-Life; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Prodrugs; Sarcoma, Experimental

1991
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
    International journal of radiation oncology, biology, physics, 1991, Volume: 21, Issue:2

    Topics: Administration, Oral; Animals; Combined Modality Therapy; Injections, Intraperitoneal; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental

1991